Research

Area 3

Cholestasis and bone pathology

Team leader

Strategic objectives

  1. Study of the epidemiology, pathogenesis, diagnosis and treatment of adult chronic cholestatic disorders and autoimmune hepatitis.
  2. Knowledge of the pathogenic mechanisms underlying pruritus and osteoporosis in primary biliary cirrhosis.
  3. Investigation of the pathogenic and therapeutic aspects of metabolic bone diseases.
  4. Definition of the therapeutic potential of different artificial liver support procedures in liver failure.

Main lines of research

RESEARCH GROUP CHOLESTASIS

  1. Epidemiology, natural history and therapeutic response of chronic cholestatic disorders in adults.
  2. Evaluation of the factors conditioning treatment response, and proposition of new treatment regimens in patientsshowing suboptimum response to ursodeoxycholic acid.
  3. Pruritus in chronic cholestasis and treatment response to albumin dialysis.
  4. Pathogenesis of osteoporosis and fracture development in primary biliary cirrhosis and other chronic cholestatic disorders.
  5. Evaluation of the safety and efficacy of different bioartificial liver and hepatic support systems in treating acute liver failure and exacerbated chronic liver failure.

RESEARCH GROUP BONE METABOLIC DISEASE

  1. Osteoporosis in premenopausal women and in males. Study of the clinical characteristics and mechanisms involved in the development of the disorder.
  2. Osteoporosis in primary biliary cirrhosis. Clinical and “in vitro” analysis. Evaluation of the key factors in the development of low bone mass and fractures, and proposal of new therapeutic protocols.
  3. Osteoporosis in liver transplantation.
  4. Evaluation of vertebroplasty as treatment for osteoporotic vertebral fractures.
  5. Evaluation of bone remodeling regulators
  6. on the pathogenesis of osteoporosis.

Research Group

Cholestasis

Albert Parés

(HCB)

  1. Epidemiology, natural history and therapeutic response of chronic cholestatic disorders in adults.
  2. Evaluation of the factors conditioning treatment response, and proposition of new treatment regimens in patients showing suboptimum response to ursodeoxycholic acid.
  3. Pruritus in chronic cholestasis and treatment response to albumin dialysis.
  4. Pathogenesis of osteoporosis and fracture development in primary biliary cirrhosis and other chronic cholestatic disorders.
  5. Evaluation of the safety and efficacy of different bioartificial liver and hepatic support systems in treating acute liver failure and exacerbated chronic liver failure.

Research Group

Bone metabolic disease

Núria Guanyabens

(HCB)

  1. Osteoporosis in premenopausal women and in males. Study of the clinical characteristics and mechanisms involved in the development of the disorder.
  2. Osteoporosis in primary biliary cirrhosis. Clinical and “in vitro” analysis.
    Evaluation of the key factors in the development of low bone mass and fractures, and proposal of new therapeutic protocols.
  3. Osteoporosis in liver transplantation.
  4. Evaluation of vertebroplasty as treatment for osteoporotic vertebral fractures.
  5. Evaluation of bone remodeling regulators on the pathogenesis of osteoporosis.